Jackson et al., Long-term non-progression in children with HIV
Long-term non-progression in children with HIV: estimates from international cohort data A recent study published in AIDS, Jackson et al. examined data from 13 European countries and Thailand through the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) to estimate the probability of long-term non-progression (LTNP) in the absence of ART, using historical cohort data […]
Young et al., Liver fibrosis regression in coinfection
Liver fibrosis regression in people living with HIV after successful treatment for hepatitis C In the frame of the InCHEHC Collaboration, Young et al. assessed the extent of liver fibrosis regression after successful treatment of hepatitis C virus (HCV) infection in persons with HIV. They included individuals with HIV/HCV who achieved sustained virologic response after […]
Rein et al., Verwendung von Integrase-Strangtransfer-Inhibitoren und kardiovaskuläre Ereignisse bei Erwachsenen mit HIV
Verwendung von Integrase-Strangtransfer-Inhibitoren und kardiovaskuläre Ereignisse bei Erwachsenen mit HIV  Gemäss internationalen Richtlinien stellen Integrase-Hemmer wie Dolutegravir oder Bictegravir den wichtigsten Grundpfeiler der HIV-Therapie weltweit dar.  Die überwiegende Mehrheit aller Personen mit HIV, die heutzutage eine Therapie beginnen, erhalten eine solche Behandlung. Ebenso werden aufgrund der sehr guten Verträglichkeit und hohen Wirksamkeit weltweit die meisten […]
Béguelin et al., Frequent HBsAg clearance during tenofovir therapy in PWH
Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection Long-term antiretroviral therapy (ART) with tenofovir has proven effective not only in controlling HIV but also in suppressing hepatitis B virus (HBV) replication in people living with HIV (PWH) who are coinfected with HBV. However, achieving functional cure […]
Haas et al., Late re-engagement into HIV care
Late re-engagement into HIV care among adults in the swiss HIV cohort study Antiretroviral therapy (ART) has significantly improved both life expectancy and quality of life for people living with HIV. However, maintaining continuous use of ART can be challenging, and some individuals disengage from healthcare over time. In a recent study published in JAIDS, […]
Tusch et al., Mortality in PWH from 1999 through 2020
Trends in mortality in people with HIV from 1999 through 2020: a multicohort collaboration In this study, the authors explored how mortality among people living with HIV has evolved over two decades, from 1999 through 2020. They analyzed data from 55’716 adult participants from two international cohort collaborations covering countries in Europe, Australia, and the […]
Kraef et al., Mortality among PWHIV in Europe
All-cause and AIDS-related mortality among people with HIV across Europe from 2001 to 2020: impact of antiretroviral therapy, tuberculosis and regional differences in a multicentre cohort study This large European study looked at how the death rates of people living with HIV changed from 2001 to 2020, and what factors influenced these outcomes. Researchers followed […]
Marinosci et al., Dolutegravir associato a emtricitabina nel confronto con una classica triterapia antiretrovirale
Efficacia e sicurezza di dolutegravir associato a emtricitabina nel confronto con una classica triterapia antiretrovirale nel mantenere la soppressione dell’HIV Negli ultimi anni, la biterapia è diventata un’alternativa interessante alla classica triterapia antiretrovirale per il trattamento dell’infezione da HIV. La biterapia è stata raccomandata nel 2021 dalla società europea dell’AIDS (EACS) e della Food and […]
Marinosci et al., Dolutégravir associé à l’emtricitabine par rapport à une thérapie antirétrovirale combinée
Efficacité et sécurité du dolutégravir associé à l’emtricitabine par rapport à une thérapie antirétrovirale combinée pour le maintien de la suppression du VIH Ces dernières années, la bithérapie est devenue une alternative viable à la trithérapie antirétrovirale classique pour le traitement de l’infection par le VIH. Recommandée par la Food and Drug Administration (FDA) et […]
Marinosci et al., Dolutegravir in Kombination mit Emtricitabin im Vergleich zu einer ART-Kombinationstherapie
Wirksamkeit und Sicherheit von Dolutegravir in Kombination mit Emtricitabin im Vergleich zu einer antiretroviralen Kombinationstherapie zur Aufrechterhaltung der HIV-Suppression In den letzten Jahren hat sich die Zweifachtherapie als gangbare Alternative zur klassischen antiretroviralen Dreifachtherapie zur Behandlung von HIV-Infektionen etabliert. Sie wird von der Food and Drug Administration (FDA) und der Europäischen AIDS-Gesellschaft (EACS) empfohlen und […]